January 9, 2025 10:19 AM ESTUpdated 11:25 AM
News Briefing

Num­ab ex­tends its Se­ries C; AnaC­ar­dio rais­es $19M for its heart fail­ure drug

ENDPOINTS

Plus, news about Rheuma­Gen and Ry­bo­Dyn:

Num­ab Ther­a­peu­tics brings in $55M: The Swiss biotech ex­tend­ed its Se­ries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sion­na and Odyssey end JPM week with IPO fil­ings

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

An­oth­er US biotech emerges with drug can­di­date from Chi­na-based Keymed

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Ex­it­ing Medicare di­rec­tor ex­pects cur­rent law to guide next price ne­go­ti­a­tions

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times